ARK Invest, led by renowned investment visionary Cathie Wood, has made a considerable pivot from technology stocks to the emerging field of biotech and gene editing. On November 4, 2025, Wood’s firm executed a series of major trades, with a clear indication of their growing confidence in genomic medicine companies such as CRISPR Therapeutics and Beam Therapeutics.
From Tech to Biotech: A Strategic Evolution
According to ARK Invest’s daily trading reports, the company allocated more than $17 million in biotech investments, significantly outweighing their $7.3 million disposition in technology stocks. The bold move reflects ARK’s belief in the transformative potential of gene editing and genomic medicine.
Key Biotech Investments
The standout trade of the day was ARK’s purchase of 162,327 shares of CRISPR Therapeutics, valued at $10.06 million. Meanwhile, the company also acquired 291,001 shares of Beam Therapeutics for $7.06 million. Both investments flowed through ARK’s ARK Genomic Revolution ETF (ARKG), which focuses on advancing genomics-based innovation.
CRISPR Therapeutics and Beam Therapeutics are leaders in the gene-editing space, working on pioneering therapies aimed at curing complex diseases. These sizeable investments signal ARK’s confidence in disruptive innovations that could redefine modern medicine.
Reduced Focus on Traditional Tech Stocks
In a noteworthy departure from technology, ARK reduced its holdings in several key tech firms:
- Teradyne: Sold 27,423 shares valued at $5.02 million.
- Roku: Trimmed 15,362 shares worth $1.67 million.
- SoFi Technologies: Reduced the position by 20,485 shares, valued at $627,455.
The tech stock sales were executed through ARK’s flagship ETF, ARKK, signaling an effort to rebalance exposures away from maturing sectors.
Increased Cryptocurrency Exposure
Additionally, ARK Invest increased its portfolio allocation in digital assets, purchasing 23,963 shares of Bullish, a cryptocurrency-anchored financial services firm. This investment, valued at $1.20 million, highlights ARK’s broader interest in blockchain technologies and digital asset innovations.
Why Gene-Editing Stocks? The Future of Medicine
Gene editing has garnered attention due to its groundbreaking potential in treating genetic diseases. Innovations like CRISPR and base-editing technologies—spearheaded by companies including CRISPR Therapeutics and Beam Therapeutics—can address previously incurable ailments. ARK Invest’s focus on these companies aligns with their ethos of supporting transformative, high-growth industries.
If you’re intrigued by the power of gene editing, check out “The Code Breaker” by Walter Isaacson, an excellent book exploring the technology’s impact on humanity.
Final Thoughts
Cathie Wood’s calculated move to increase exposure in genomics and gene-editing stocks positions ARK Invest as a visionary player in the life sciences sector. Their focus on disruptive innovation could prove to be a winning strategy as biotech advances promise to reshape healthcare over the coming decades.
